LONDON -- Scancell Holdings reported first-half figures today, and brought us news of "encouraging preliminary results from part 1 of the Phase 1/2 clinical trial" for its lead vaccine SCIB1. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results